Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2
- PMID: 6088797
- PMCID: PMC255840
- DOI: 10.1128/JVI.51.3.747-753.1984
Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2
Abstract
Herpes simplex virus type 2 is a common human venereal pathogen which causes lethal neurological illness after intravaginal inoculation into BALB/cJ mice. To investigate whether an attenuated, nonlethal strain of this virus would confer immunity after inoculation of mice, we constructed a strain containing a partial deletion of the thymidine kinase gene, which is necessary for viral replication and spread in sensory ganglia. Unlike its wild-type counterpart, this deletion-containing strain of herpes simplex virus type 2 caused mild clinical disease and was not lethal when studied in an age-dependent murine model of intravaginal infection. Furthermore, after intravaginal infection, the deletion-containing strain could not be isolated from sensory ganglia at a time when wild-type virus was abundant. Of greater significance, intravaginal inoculation with the deletion-containing strain rendered mice completely resistant to rechallenge with a 10-fold 50% lethal dose of wild-type virus. These results suggest that a strain of herpes simplex virus type 2 containing a deletion of the thymidine kinase gene will be useful in studying the cellular basis of mucosal immunity in the genital tract.
Similar articles
-
Expression of immunity to intravaginal herpes simplex virus type 2 infection in the genital tract and associated lymph nodes.Arch Virol. 1987;93(1-2):51-68. doi: 10.1007/BF01313893. Arch Virol. 1987. PMID: 3813891
-
T lymphocytes in genital lymph nodes protect mice from intravaginal infection with herpes simplex virus type 2.J Infect Dis. 1989 Mar;159(3):460-6. doi: 10.1093/infdis/159.3.460. J Infect Dis. 1989. PMID: 2783720
-
Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2.J Gen Virol. 1990 Jul;71 ( Pt 7):1497-504. doi: 10.1099/0022-1317-71-7-1497. J Gen Virol. 1990. PMID: 2165134
-
The quest for a herpes simplex virus vaccine: background and recent developments.Vaccine. 1986 Sep;4(3):138-50. doi: 10.1016/0264-410x(86)90001-0. Vaccine. 1986. PMID: 3020819 Review.
-
Genetically engineered herpes simplex virus vaccines.Prog Med Virol. 1985;31:84-108. Prog Med Virol. 1985. PMID: 2982176 Review. No abstract available.
Cited by
-
In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model.J Virol. 1999 Jan;73(1):501-9. doi: 10.1128/JVI.73.1.501-509.1999. J Virol. 1999. PMID: 9847356 Free PMC article.
-
The herpes simplex virus type 1 (HSV-1) a sequence serves as a cleavage/packaging signal but does not drive recombinational genome isomerization when it is inserted into the HSV-2 genome.J Virol. 1992 Dec;66(12):7505-10. doi: 10.1128/JVI.66.12.7505-7510.1992. J Virol. 1992. PMID: 1331535 Free PMC article.
-
Immunity to vaginal herpes simplex virus-2 infection in B-cell knockout mice.Immunology. 2000 Sep;101(1):126-31. doi: 10.1046/j.1365-2567.2000.00080.x. Immunology. 2000. PMID: 11012763 Free PMC article.
-
The lack of RNA-dependent protein kinase enhances susceptibility of mice to genital herpes simplex virus type 2 infection.Immunology. 2006 Aug;118(4):520-6. doi: 10.1111/j.1365-2567.2006.02403.x. Immunology. 2006. PMID: 16895559 Free PMC article.
-
Herpes simplex virus-2 dynamics as a probe to measure the extremely rapid and spatially localized tissue-resident T-cell response.Immunol Rev. 2018 Sep;285(1):113-133. doi: 10.1111/imr.12672. Immunol Rev. 2018. PMID: 30129205 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical